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Medecins Sans Frontieres (MSF) is an international, independent medical nongovernmental organization. One
way in which MSF acts to improve patient care is to assist in the identification and development of adapted
and appropriate tools for use in resource-limited settings. One strategy to achieve this goal is through active
collaborations with scientists and developers, to make some of the field needs known and to help define the
medical strategy behind the implementation of new diagnostic tests. Tests used in the field need to be effective
in often extreme conditions and must also deliver high-quality, reliable results that can be used in the local
context. In this article, we discuss some patient and health care provider needs for human immunodeficiency
virus (HIV) load measurement in resource-limited settings. This is just one of the areas in which effective,
quality tools are desperately needed, not only by MSF and other international nongovernmental organizations,
but also by many other health service providers. We hope that, by clearly defining the needs of patients in
MSF clinics—as well as we can assess this—and by explaining why these tools are needed, how they should
perform, and how their results can be integrated into a program, we will encourage the development of such
tools and hasten their implementation in areas where they are so urgently needed.
VIRAL LOAD TESTS
Why test viral load? Viral load testing can be used
to diagnose human immunodeficiency virus (HIV) in-
fection in infants (age, !18 months). A nucleic acid test
is required to distinguish between the children who
have residual circulating antibodies from their mother
and those who are infected with HIV. Polymerase chain
reaction (PCR) techniques using dry blood spots have
been shown to be accurate, reproducible, and feasible
in resource-limited settings [1, 2], but routine imple-
mentation has been challenging, because many logis-
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tical issues must be addressed, such as sending the sam-
ple, receiving the results, and identifying suitable
laboratories to perform the testing. A point-of-care
(POC) viral load test would help reduce or remove
these constraints.
Detection of HIV RNA in infants is usually techni-
cally easier than such detection in adults, because viral
load is typically very high (1100,000 copies/mL) and
the test results do not need to be quantitative. A simple
“yes/no” test with a detection threshold of 1000 copies/
mL in whole blood samples has been proposed [3].
Viral load is also frequently used to monitor treat-
ment efficacy. In well-resourced settings, viral load mea-
surement every 3–6 months is considered to be the
standard of care [4]. The information is used to assess
treatment efficacy and adherence and to help in the
decision about when to switch to a different, more
potent regimen. Although, to date, the World Health
Organization does not recommend routine use of viral
load testing in resource-limited settings, new 2006
guidelines recognize that “CD4 and plasma HIV-1 RNA
testing are not luxuries. They are important tools sup-
porting the delivery of optimal care and, in the setting
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of the public health approach, are invaluable measures of pro-
gramme monitoring and performance” [5, p 81].
The best way to use viral load information in a context in
which therapeutic options are limited has not been fully de-
termined. In resource-rich settings, treatment involves intensive
virological suppressive strategies supported by routine use of
viral load measurement and unrestricted access to antiretroviral
therapy. Clearly, this strategy is not transposable to resource-
constrained settings. For a combination of financial, logistical,
and human resource–related reasons, most settings cannot per-
form viral load testing at the present time. Current technologies
are very expensive and require delicate instruments, cold chain,
and stable electricity, which are not available in areas where
the majority of the patients reside. Samples can be shipped; the
samples must be received rapidly by the reference laboratory,
and many countries have few or no laboratories with the ability
to perform testing. In many settings, shipping of samples is
not possible and is always a logistical challenge. Because of the
challenges in implementing the simpler and better characterized
dry spot technique for infant diagnosis, shipping of samples
for viral load is unlikely to be feasible or widely used. In ad-
dition, the lack of human resources to evaluate and provide
treatment for the overwhelming number of patients needing
HIV care means that services, when available, are often strained
to their limit.
However, in the context of patients receiving chronic, life-
long treatment, often in precarious economic, social, or political
conditions, which make adherence or program stability chal-
lenging [6], and in settings where therapeutic options are lim-
ited, the use of viral load testing is increasingly considered to
be critical in establishing whether a patient needs a therapy
change [7]. Several monitoring strategies are now being ex-
plored that use CD4+ T cell count in combination with clinical
and biochemical markers, but these have shown poor predict-
ability of treatment failure. The consensus remains that optimal
treatment for patients requires both CD4+ T cell count and
viral load measurements [3]. Some researchers have even ar-
gued that viral load is of more critical importance than is CD4+
T cell count [8]. Moreover, in settings where human resources
are limited, knowledge of a patient’s viral load allows the health
care provider to perform a “triage,” dedicate more time to
patients with moderate-to-high viral loads, and refer patients
with consistently suppressed HIV RNA to lay counsellors. Pa-
tients with elevated viral load early after treatment initiation
could be targeted for intensive adherence counselling, preserv-
ing the use of the first-line therapy.
Use of viral load testing is further complicated by the limited
treatment options available in resource-limited settings. Be-
cause viral load tests remain expensive and because of the sig-
nificantly higher cost of second-line drugs, many programs in
developing countries are hesitant to use viral load testing. The
use of viral load testing and its integration into patient care is
not simple or clear: the number of tests and frequency of test-
ing, the threshold for switching to second-line treatment, and
the clinically optimal level of viral suppression need to be an-
alyzed using retrospective cohort data. Care must be taken in
designing these studies so that they involve HIV subtypes en-
demic in the populations, rather than using results of studies
performed in other settings or investigating other subtypes.
Viral load testing for adults receiving antiretroviral treatment
should not only be seen as addressing when to switch therapy,
it should also be considered as a way to decide not to unnec-
essarily modify a first-line regimen in the context of concom-
itant infection or CD4+ T cell count decreases, which are usually
thought to be poor surrogate markers for treatment failure.
Indeed, studies have shown that ∼50% of patients who would
have had therapy switched on the basis of CD4+ T cell count
and clinical condition (as recommended by the World Health
Organization) have, in fact, fully suppressed HIV RNA [3].
It is generally accepted that viral load testing is especially
important in at least 2 situations: (1) to confirm viral sup-
pression in pregnant women to lower the risk of mother-to-
child transmission and (2) in diagnosis during infancy in coun-
tries with a high prevalence of HIV infection. However, if a
simple, low-cost, and reliable viral load test existed that could
be used in countries with a high burden of HIV infection,
integration of the test into routine patient care would improve
the management of HIV infection, and use of the test in other
contexts could be broadened.
Existing viral load technologies in resource-limited settings.
Because of the level of sophistication required for viral load
measurement, most resource-limited settings do not have access
to suitable facilities in the locations where they would be most
needed. In remote laboratories, setting up, running, and ser-
vicing of simplified machines for CD4+ T cell count measure-
ment are already significant challenges, even in provincial hos-
pitals, leaving machines for viral load measurement almost
totally absent from routine equipment lists. Because the medical
demand for viral load testing for follow-up of patients is in-
creasing rapidly, some facilities choose to contract out the test-
ing to local laboratories that are sufficiently equipped and sup-
ported mostly by overseas academic institutions. This has been
the case for MSF projects in such countries as South Africa,
Cameroon, Cambodia, and Thailand.
Storage and transportation of samples is still a problem, as
are delays for answers from overloaded laboratories. Such qual-
ified laboratories are not available in all settings, and for the
most part, viral load testing is simply not feasible under existing
conditions. In addition to the high prices charged, it is often
difficult to obtain precise and reliable information about the
quality assurance procedures implemented in many laborato-
ries, and the reliability of the results can be questionable. In-
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Table 1. Specifications of Current Viral Load Technologies
Specification Desirable Acceptable Current state of the arta
Specialized laboratory facilities No No Required
Closed system: amplicon containment to prevent
contamination
Yes Yes Some
Shelf life 18 Months at 37C 12 Months at 30C 3–18 Months at 80C to
4C
Cold chain transportation No No Required
Refrigerated storage No No Required
Ease of use
Sample preparation Integrated Stand-alone (!8 steps) …
No. of steps !5 !10 130
Total assay time, h !2 !3 4–22
Training time !1 day !2 days 11 week
Precision pipetting No No Required
Additional reagents and disposables No No Required
Sample type Whole blood and plasma Whole blood and plasma Plasma and dried blood spots
Lower limit of sensitivity, copies/mL
Heel or finger prick 1000 4000 Not available
Plasma 500 2000 400
Manufacturing cost per test, US$ !10 !12 Not applicable
Cost per test, US$ Not available Not available 30–200
Manufacturing cost of equipment for amplification
and detection (dipstick reader included; sample
preparation optional), US$
!1000 !2000 Not available
Equipment cost, US$ Not applicable Not applicable 15–60,000
Product licensing
Qualitative assay CE mark CE mark CE mark and/or FDA approval
Semiquantitative assay CE mark WHO, UNDP CE mark and/or FDA approval
NOTE. FDA, Food and Drug Administration; UNDP, United Nations Development Programme; WHO, World Health Organization.
a Currently available HIV nucleic acid–based tests.
ternationally recommended quality assurance procedures (such
as those promoted by the World Health Organization) have
been sometimes found not to be robust and comprehensive
enough for unsupported laboratories [9]. Reagents and equip-
ment are often lacking or expired because of the challenges of
ensuring regular and adequate provision of the necessary items.
Existing viral load technologies are poorly adapted for use in
most resource-limited settings. All of the 4 frequently used
systems in high-income countries—the Abbott real-time HIV-
1 PCR assay, the Bayer Versant HIV-1 RNA assay (version 3.0;
bDNA), the bioMe´rieux NucliSENS HIV-1QT assay (nucleic
acid sequence–based amplification), and the Roche Amplicor
HIV-1 Monitor assay (version 1.5; reverse-transcription
PCR)—require sensitive equipment, highly trained staff, and
good infrastructure, monitoring, and support (Table 1); these
conditions are lacking in most countries with a high burden
of HIV infection. Moreover, the accuracy of these tests for
detection of non-B subtypes has been questioned [10, 11].
Field-appropriate viral load tests: POC and other strategies.
How can appropriate, high-quality test results be provided in
the most cost-effective way possible? One class of solution is
the POC test. POC tests are diagnostic tests that are performed
near the patient.
POC tests have the advantage of requiring less laboratory
infrastructure, are potentially cheaper, and can be designed to
be simple and easy to use and interpret. The quick result and
low laboratory burden can help reduce the workload for lab-
oratories and streamline care in settings where large numbers
of patients are treated daily. However, in addition to improving
the standard of care, a test that can be performed while the
patient is at the clinic means that fewer patients are lost to
follow-up, and the burden on patients is reduced.
Regardless of the technology solution chosen, the test must
perform in local conditions (eg, heat, humidity, dust, and pos-
sible lack of laboratory, running water, or electricity) and not
be simply imported from resource-rich settings and force-fit
to local conditions for want of a better solution. Another im-
portant characteristic is that the tools are appropriate to clinical
decision making. This means that they deliver a result that is
useful for the health care provider to use in making clinical
decisions and not results that are ambiguous or unnecessary.
Current practice in resource-rich settings is to maintain an
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undetectable viral load in patients. However, the threshold for
undetectable differs depending on the sensitivity of the test
used, and the true clinical significance of the viral load infor-
mation continues to be debated [12–14].
The choice of a cutoff value may depend on the clinical use.
The threshold chosen for a switch to second-line therapy has
to be specific (eg, switch therapy for all those who need it),
whereas a threshold to assess good treatment efficacy despite
confounding clinical events or shortly after treatment initiation
has to be set very low, to detect problems with treatment ad-
herence. In addition, natural variation in the body can result
in a peak of viral load in a single test, implying that repeated
viral load testing may be required [13, 15, 16].
Viral load testing: programmatic issues. As experience in
running HIV programs increases, MSF has identified a number
of contexts in which patients’ needs should influence the design
of testing strategies and technologies. Some of the undecided
clinical and operational issues are:
Routine viral load testing or testing triggered by a clinical
event or immunological failure
How often should the test be performed? This impacts on
the workload at the health care facility or clinic and the
overall cost of the program and must be determined in
conjunction with the medical program
How to integrate viral load in the complex algorithm of the
decision about when to switch therapy
The availability of second-line drugs
Where will patients be followed up and where are the tests
to be performed?
What cost a program can bear relative to the cost of shipping
samples or of not offering viral load testing
Should viral load testing be performed routinely after ini-
tiation of antiretroviral therapy to monitor adherence? Is
testing only necessary to assess failure based on clinical or
immunological grounds?
There is also a crucial but often underappreciated need to
prepare the end users and health care systems for emerging
tests to ensure good uptake. For example, the introduction of
semiquantitative or qualitative viral load testing will require
training, information, and follow-up, as well as implementation
strategies, pilot projects, and operational research. The devel-
opment of a test for triage could decrease the time to admin-
istration of treatment to the individual patient and significantly
reduce the burden on overextended health care systems.
THINKING AHEAD
The international community is well aware of the extent of the
HIV epidemic and the urgency for action, and this effort has
to be sustained. Can we imagine other models to address this
unprecedented global emergency, such as home-based viral load
testing, analogous to current diabetes home testing, or com-
munity centers with reflex referral? In this reflection, we need
to consider the target populations based on the medical needs:
how often is testing really necessary? Sustainability is crucial,
and solutions that use local resources or develop open-source
or adaptable technologies should be favored over commercial
solutions. Designing a comprehensive strategy including pro-
vision for scale-up, decentralization, and triage would be made
significantly easier if such a test was available, even if the test
had relatively low sensitivity.
GETTING AHEAD OF THE CURVE
We need to develop technologies to drive better patient care.
A POC viral load test is a first step, but we can already aim
for a test that would provide not only HIV RNA levels but also
the presence or absence of key mutations. Key drug resistance
mutations develop when ongoing viral replication occurs under
the pressure of drugs. The information provided by such a test
will then have a dual purpose if (1) a patient has a detectable
HIV RNA level and is infected with virus with a drug resistance
mutation (adherence is likely to be good, but treatment is fail-
ing), (2) a patient has a detectable HIV RNA level and has no
drug resistance mutation (poor adherence), and (3) drug re-
sistance mutations can give information on a more global pub-
lic health level about which mutations are prevalent in a specific
population, with a specific HIV subtype and using specific
drugs, and therefore, give information on the usefulness of
standardized second-line treatment.
DEFINING THE SPECIFICATIONS AND
BUILDING CONSENSUS
We need a broad-based commitment to the development of
field-appropriate viral load testing if we hope to develop ef-
fective solutions. Developing tests and validating them, as well
as ensuring their quality and eventually paying for their man-
ufacture, shipping, and safe and environmentally friendly dis-
posal will take commitment, funding, and collaboration among
scientists, medical personnel, national program managers, and
all other stakeholders.
CONCLUSIONS
Viral load testing is relevant only if treatments are available and
the development of diagnostics and treatments are comple-
mentary and crucial. Access to both must also be assured for
the optimal long-term management of HIV disease. There is
also a need for different tools in different contexts. The spec-
ifications of a test are based on the need for a routine test to
determine (1) when to switch therapy (eg, higher threshold)
and (2) when not to switch therapy (eg, treatment initiation
or for assessing adherence when CD4+ T cell count is decreas-
ing). In prevention of mother-to-child transmission programs,
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the needs may be slightly different: the goal is to maintain an
undetectable viral load in the mother or, in the absence of
prophylaxis, to diagnose viral infection in the infant (in whom
viral load levels are usually very high). A test used to triage
patients would be very useful both for individual care and to
relieve some of the pressure on overburdened health care
systems.
In parallel, we need to strengthen the use of existing so-
phisticated technologies at upper levels of care. It is important
to have access to reference-level facilities in all countries and
to support and maintain the technical and technological ca-
pacity of health care systems. A sustainable supply of tests and
appropriate quality assurance systems are key.
The impact of a test also depends on preparation of the end
users to adopt new technologies and the integration of the test
result into patient treatment. Sustainability, affordability, en-
vironmental impact, and waste disposal are important factors
to be considered early in the development of a test.
We can best hope to develop appropriate viral load tech-
nologies through a collaborative, integrated approach. How-
ever, many of the issues raised here in relation to viral load
testing are relevant to the development of field-adapted diag-
nostic tools and their integration into health care strategies for
a number of other diseases.
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